Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Really because that was in the S1A that they most recently filed and it says as of January 23 as if it’s in effect?
How can they file an S1A and say those things before the split even occurs
As of January 20, 2023, there were (i) 1,448,177 shares of our Common Stock issued and outstanding,
Does that mean 536 million shares are owned by insiders in management and retail only owns 1,448,177 shares ?
The only way they’re able to sell 150,000 shares in between the ask and the bid is if they have market makers working with them
Why because this is their last one because they’re all in the late 60s lol
? Approximately $2,000,000 to the manufacturing and IND enabling activities to file an IND and, if the IND is approved, complete a phase 1 clinical trial of dry age-related macular degeneration (AMD) and Geographic Atrophy. Pursuant to the CRADA (see section of this Prospectus entitled “Product Development” – Degenerative Eye Diseases” for more information), our contribution to the first clinical trial will be a maximum of $115,000, with the balance to be covered by the National Eye Institute;
So this is the same with the exception of the wages and earnings or salary for each Paul, Michaels, Barry, Ginsberg, and Richard car, all of their employment agreements, and in August 2023
On October 1, 2020, the Company entered into an employment agreement with I Richard Garr to serve as CEO and General Counsel for a term of three (3) years beginning on September 1, 2020 and expiring on August 31, 2023 (“Garr Employment Agreement”). On August 26, 2021, the Board additionally appointed Mr. Garr to serve as CFO of the Company. Pursuant to the Garr Employment Agreement, Mr. Garr receives an annual salary of $360,000 per annum, which was increased by the Board to $420,000 per annum, effective September 1, 2021. The Garr Employment Agreement states that the Company will accrue his outstanding salary until such time as the Company receives adequate funding. Mr. Garr received all compensation as an independent contractor until August 1, 2021, when Mr. Garr began receiving his salary as an employee. Effective September 30, 2021, the Board agreed to provide an additional $1,500 per month healthcare / transportation stipend to all employees,
Notice how many shares of common stock are issued and outstanding
Our authorized capital stock consists of 1,100,000,000 shares of Common Stock, $0.0001 par value per share, and 200,000,000 shares of preferred stock, $0.0001 par value per share. As of January 20, 2023, there were (i) 1,448,177 shares of our Common Stock issued and outstanding, (ii) 227,000 shares of Series B Preferred Stock issued and outstanding and (iii) 30,000,000 shares of Series C Preferred Stock issued and outstanding.
Wow
We were incorporated in the state of Nevada on June 29th, 1995, as Frozen Assets, Inc. Subsequently the Company changed its name to Growth Industries, Inc. in March 1998, Fragrance Express, Inc. in June 1998, National Boston Medical in October 1998, Storage Innovation Technologies in May 2004, and Connectyx Technologies in October 2007, and as of October 31, 2007 reincorporated in the state of Florida. In April 2017, the Company voluntarily dissolved its wholly owned subsidiary USA Medical Monitoring, LLC (“USA Medical”), which was a Florida Limited Liability Company. In May 2019, the Company voluntarily dissolved its wholly owned subsidiary Connectyx Technologies Corp. (“CTP”), which was a Florida Corporation. The Company remains active in the state of Florida. On November 23, 2020, the Company changed its name to Curative Biotechnology, Inc.
This is cut and pasted directly from the latest S1 on January 25
As of the date of this Prospectus, we have completed preliminary toxicology, pharmacokinetics and tolerance studies in one species (rabbit) with a non-clinical grade drug. We will need to replicate these studies under Good Laboratory Practice conditions in rabbits and potentially dogs and we will need to complete a manufacturing plan as part of our IND application process. Thereafter, we will need to manufacture clinical grade drug in large enough quantities to conduct and complete the proposed clinical trial.
So, like I said, they’ve done some animal studies, but they still have to do the good laboratory practice studies and then come up with a manufacturing plan, and then manufacture enough medicine to do the clinical trials with the NEI
Call me skeptical, but I’ve been here over three years now and I’ve seen very little progress in that time and no transparency almost as if management isn’t concerned about investors , and I’m afraid come April they’re going to say we don’t have enough money to continue forward so at this point we’re going to have to dissolve and in the S one it clearly states you can look it up for yourself. It says in the event that the company can no longer go forward and dissolves preferred shareholders will get $400 a share that is exactly what it says in the S1 and that those shares will take precedence over common shareholders. If I hadn’t seen that in the S1 I might have more hope, but that was the last one issued and they have not issued a new one yet some people said it was a typo, but the fact of the matter is is, it is in writing which means it’s a legal document …..that would pretty much take all investors money
They never said anywhere in any literature or PR‘s that they were doing the animal toxicology studies as part of the Crada. It did say they were going to do the animal toxicology studies, and then do human clinical trials with the national Institute as part of the Crada, but it’s my understanding they had to manufacture enough of the eyedrops to be able to do the clinical trials, and we’ve heard no news. If they’re currently doing clinical trials, would they not announce that they have started the clinical trials I mean it would be stupid to not announce something like that so I’m assuming they’re not yet
I’m not selling for .013 that’s less than what I bought it for but if it got up to 3 1/2 or four cents, I would gladly sell it
This is a lie they haven’t even started the Crada with NEI , the only thing done so far is was animal toxicology wich enables them to start the Crada once enough of the eyedrop formulation is manufactured
Do they have any plan at all or are they just gonna let shareholders hang out to dry how about some transparency?
What good does the Crada do? If the company gets dissolved because they can’t raise money it’s like you live in a different reality or something
Big whoop and what are they doing with it? Nothing they haven’t even started it because they can’t get up listed if I could sell I would.
Nothing they said what happened has happened not one thing they haven’t met the timelines. They haven’t got the uplist or the reverse split done …….nothing ..nada
So is this company ever going to do anything or they just gonna screw investors over? Where is the effing news?
Well, besides take investors money based off fraudulent information
Somebody just sold 180,000 shares at .0130 that’s not good if they were willing to sell that low
Has anyone talked to the national Institute to see if this Crada is credible?
To ensure that the flow of information about issuers and securities offerings is not unduly limited, the SEC has adopted a number of rules to permit issuers to communicate during this period about matters other than the registered securities offering (including the release of factual business information), as well as rules that permit issuers to provide limited public information about their plans to engage in, or the status of, a registered securities offering.,,
You can’t be in a quiet. Forever that’s why they were able to release news you’re just giving us excuses.
With an IPO, the quiet period stretches from when a company files registration paperwork with U.S. regulators through the 40 days after the stock starts trading.
With publicly-traded companies, the quiet period refers to the four weeks before the end of the business quarter.
So it says nothing about a secondary offering, which means if we’re in a quiet. It’s simply because earnings are close which means they planned their prospectus around earnings knowing that earnings would be due around the middle of April, which would give them an excuse for a quiet. To possibly close shop.
So our investor relations person doesn’t even know how to quiet. Works. It only works with an IPO otherwise, on a publicly traded company the only other quiet. Is the four weeks prior to earnings
All these bios running, and we should be one of them, but yet we’re not because our management is incompetent
I have and it doesn’t say anything about CUBT or why they would be in a quiet. The quiet period last for a month after the S1 I think you’re just purposely trying to keep people in the stock until it’s bankrupt, which is not a very decent thing to do
If that’s true, then copy and paste wherever it is you find that copy and paste it and let’s see what it says because I haven’t been able to find anything that backs up what you’re saying
They couldn’t get up listed or get the offering done so all the sudden they’re in a quiet. Yeah right nice excuse.
That is a lie. They are not in a quiet. The S one hasn’t been in effect for over a month now.
OK then tell me why we would be in a quiet period….They haven’t filed an S1 and it’s been over a month so tell me why there would be a quiet period …..Oh that’s right you can’t.
There is no quiet period That’s a lie.
There’s nothing to talk about no transparency no news no CEO blogs nothing
He knew that bid would not fill nobody wants to sell that cheap. How about buy another million shares at $.019
Strange how the price never goes up
These market makers are making it hard for anyone to buy with a half penny spread the ask is too high compared to the bid
Do you know you would think Richard Barry and Paul would take a little bit of that money that they’re supposed to be paid for their extravagant lifestyles coming from the offering and instead of using that for salaries how about pay yourself 150,000 a year and use the rest of it for the company
Please do three years is longer than I planned on holding and I could’ve use the money invested and something else several times over
If this would just get up to four cents, I would sell every share I own, and I wouldn’t make any more posts
Why don’t you give us some insight on what’s going on with the company? as investor relations for CUBT I would think you would know, and you obviously have skin in the game. If this company goes to zero it affects you as well. So any news would be helpful
What capital raise the last one failed and they haven’t filed a new S1 yet, it’s been two months since they announced that they completed their IND, enabling trial, and crickets